Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales

Br J Urol. 1997 May:79 Suppl 3:1-32. doi: 10.1111/j.1464-410x.1997.tb16914.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use
  • Genetic Predisposition to Disease
  • Health Care Costs
  • Hospitalization
  • Humans
  • Incidence
  • Male
  • Mass Screening / economics
  • Mass Screening / methods
  • Middle Aged
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / economics
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / therapy
  • Referral and Consultation
  • Risk Factors
  • Workload

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen